Depression in older ages: a challenging diagnosis

Depression is a serious illness affecting approximately 3% to 6% of adults over age 65 in the United States. Also depression affects a much higher percentage of people in hospitals and nursing homes. Depression in late life can be a relapse of an earlier depression, But when it occurs for the first time in older adults, it usually is a consequence of a medical illness. With coexisting medical illness, depression can be more difficult to recognize and also more difficult to endure.however  A majority of the people diagnosed with depression in primary care settings, , do not meet the diagnostic criteria for major depressive disorder.

Fatigue, lack of energy and sleep problems associated with medical conditions often mimic depressive symptoms and makes difficult the diagnose of depression in primary care settings, in older adults. Furthermore, losses of friends and loved ones and a shrinking social network in old age result in diminished social involvement, which is a common feature of depression. These problems of old age are sometimes difficult to distinguish from depressive symptoms.

The challenge of correctly identifying depression in primary care is compounded by the fact that depressed patients seen in these settings have less-clear-cut symptom profiles than those seen in specialty mental health settings, mainly because their symptoms are less severe or disabling. Some patients diagnosed with depression in primary care may meet the criteria for dysthymia or adjustment disorder with mood symptoms. Others may have mild depressive symptoms that don't reach the threshold for diagnosis of major depressive disorder. Many such patients would benefit from supportive counseling or lifestyle modification. In some cases, watchful waiting with regular follow-up may be appropriate. Yet the majority of primary care patients diagnosed with depression are simply prescribed antidepressants.

 

The guidelines discourage routine use of antidepressants for persistent subthreshold depressive symptoms or mild depression. However, clinicians may consider these medications for patients with a history of moderate or severe depression, subthreshold symptoms lasting 2 years or longer, and subthreshold symptoms or mild depression that persists after low-intensity psychosocial interventions. Medications (typically selective serotonin-reuptake inhibitors) or high-intensity psychosocial interventions, such as individual cognitive behavioral therapy or interpersonal therapy, alone or combined with medications, may be considered as a third step for patients with no response to low-intensity psychosocial interventions and those with moderate-to-severe depression. When medication has been started, the guidelines recommend continuing it at a therapeutic dose for at least 6 months after remission of an episode.

With the looming shortage of geriatric mental health care providers, general medical clinicians' role in managing older adults' mental health problems will probably increase. A nuanced approach to depression diagnosis and treatment may improve the management and outcome of geriatric depression in primary care settings. Incorporating the stepped-care approaches into generalists' training and making low-intensity psychosocial interventions more widely available may help prepare clinicians to more effectively meet future needs.

Effective treatments—including psychopharmacologic, psychotherapeutic (behavioral or counseling), and complementary and alternative therapies—and combinations of these are available for depressed patients identified in primary care settings. Cognitive-behavioral therapy (CBT) and interpersonal therapy are psychotherapeutic approaches used in the treatment of patients with major depressive disorder, with documented beneficial outcomes.

In general, evidence-based recommendation for treatment of moderate to severe depression in the primary care setting in elderly patients involves a combination of pharmacotherapy and psychotherapy, and for the treatment of mild to moderate depression, psychotherapy alone.

A Breakthrough In Depression Treatment

Research out of the University of Texas Southwestern Medical Center claims it’s found a “breakthrough” way to treat depression, which affects nearly one in 10 adults in the U.S.

Researchers led by Dr. Jeffrey Zigman, associate professor of internal medicine and psychiatry at UT Southwestern, have improved their understanding of how a certain natural antidepressant hormone referred to as ghrelin works in the brain. In their study, they point to ghrelin as a potential new antidepressant with powerful effects.

Ghrelin, known as the “hunger hormone,” arouses appetite, and has been found to contain natural antidepressant properties that appear when its levels increase due to caloric restriction. The hormone, which is produced in the stomach and intestines, can lead to the formation of new neurons in the hippocampus — a region in the brain that moderates memory, mood, and complex eating behaviors. New neurons generating in the brain is known as neurogenesis.
 

A mix of the hunger hormone, ghrelin, and the P7C3 compound could trigger the production of new neurons and work against depression/ Photo courtesy of Shutterstock

The research is preceded by a study previously completed by Zigman back in 2008, when he discovered that chronic stress causes ghrelin to increase; this led to a decrease in depression and anxiety in mice.

While increased amounts of ghrelin leads to neurogenesis, the researchers decided to add another component to the antidepressant mix. Certain compounds known as P7C3 have been shown to exhibit neuroprotective abilities, especially in people with Parkinson’s disease, traumatic brain injuries (TBI), or amyotrophic lateral sclerosis (ALS). P7C3 can also be used in battling depression — the scientists found that the compound, mixed with ghrelin, actually improved neurogenesis.

“We found that P7C3 exerted a potent antidepressant effect via its neurogenesis-promoting properties,” Dr. Pieper, associate professor of neurology and psychiatry at the University of Iowa Carver College of Medicine, said in a press release. “Also exciting, a highly active P7C3 analog was able to quickly enhance neurogenesis to a much greater level than a wide spectrum of currently marketed antidepressant drugs.”

Certain types of depression, such as those associated with chronic stress or ghrelin resistance (linked to obesity or anorexia nervosa), may be the most treatable using this new method. The scientists plan on studying this potential treatment further.

“By investigating the way the so-called ‘hunger hormone’ ghrelin works to limit the extent of depression following long-term exposure to stress, we discovered what could become a brand new class of antidepressant drugs,” Zigman noted in the press release.

How ketamine defeats chronic depression

Many chronically depressed and treatment-resistant patients experience immediate relief from symptoms after taking small amounts of the drug ketamine. For a decade, scientists have been trying to explain the observation first made at Yale University.

Today, current evidence suggests that the pediatric anesthetic helps regenerate synaptic connections between brain cells damaged by stress and depression, according to a review of scientific research written by Yale School of Medicine researchers and published in the Oct. 5 issue of the journal Science.

Ketamine works on an entirely different type of neurotransmitter system than current antidepressants, which can take months to improve symptoms of depression and do not work at all for one out of every three patients. Understanding how ketamine works in the brain could lead to the development of an entirely new class of antidepressants, offering relief for tens of millions of people suffering from chronic depression.

"The rapid therapeutic response of ketamine in treatment-resistant patients is the biggest breakthrough in depression research in a half century," said Ronald Duman, the Elizabeth Mears and House Jameson Professor of Psychiatry and Professor of Neurobiology.

Duman and George K. Aghajanian, also professor of psychiatry at Yale, are co-authors of the review.

Understanding how ketamine works is crucial because of the drug's limitations. The improvement in symptoms, which are evident just hours after ketamine is administered, lasts only a week to 10 days. In large doses, ketamine can cause short-term symptoms of psychosis and is abused as the party drug "Special K."

In their research, Duman and others show that in a series of steps ketamine triggers release of neurotransmitter glutamate, which in turn stimulates growth of synapses. Research at Yale has shown that damage of these synaptic connections caused by chronic stress is rapidly reversed by a single dose of ketamine.

The original link between ketamine and relief of depression was made at the Connecticut Mental Health Center in New Haven by John Krystal, chair of the department of psychiatry at Yale, and Dennis Charney, now dean of Mt. Sinai School of Medicine, who helped launch clinical trials of ketamine while at the National Institute of Mental Health.

Efforts to develop drugs that replicate the effects of ketamine have produced some promising results, but they do not act as quickly as ketamine. Researchers are investigating alternatives they hope can duplicate the efficacy and rapid response of ketamine.

Video: http://www.youtube.com/watch?feature=player_embedded&v=hNsIiq-5354#!

 

Journal Reference:

  1. R. S. Duman, G. K. Aghajanian. Synaptic Dysfunction in Depression: Potential Therapeutic Targets. Science, 2012; 338 (6103): 68 DOI: 10.1126/science.1222939